Needham Reiterates Buy on Taysha Gene Therapies, Maintains $7 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Gil Blum has reiterated a Buy rating on Taysha Gene Therapies (NASDAQ:TSHA) and maintained a $7 price target.
May 15, 2024 | 10:04 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Gil Blum has reiterated a Buy rating on Taysha Gene Therapies and maintained a $7 price target, indicating confidence in the company's future performance.
The reiteration of a Buy rating and the maintenance of a $7 price target by a reputable analyst suggests positive sentiment and confidence in Taysha Gene Therapies' future performance. This is likely to have a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100